175.72
-1.0273(-0.58%)
Currency In USD
| Previous Close | 176.75 |
| Open | 176 |
| Day High | 178.2 |
| Day Low | 173.01 |
| 52-Week High | 207.84 |
| 52-Week Low | 122.8 |
| Volume | 217,538 |
| Average Volume | 349,252 |
| Market Cap | 5.09B |
| PE | 35.72 |
| EPS | 4.92 |
| Moving Average 50 Days | 150.07 |
| Moving Average 200 Days | 155.43 |
| Change | -1.03 |
If you invested $1000 in Krystal Biotech, Inc. (KRYS) since IPO date, it would be worth $16,379.23 as of September 30, 2025 at a share price of $174.275. Whereas If you bought $1000 worth of Krystal Biotech, Inc. (KRYS) shares 5 years ago, it would be worth $4,048.2 as of September 30, 2025 at a share price of $174.275.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
GlobeNewswire Inc.
Sep 15, 2025 12:00 PM GMT
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United Sta
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025, in New York. Krish S. Krishn
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
GlobeNewswire Inc.
Aug 21, 2025 4:11 PM GMT
PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed t